DURECT Corp. (DRRX:NASDAQ) announced in a news release two pieces of news concerning progress of its ongoing DUR-928 Phase 2a clinical trial in patients with moderate and patients with severe alcoholic hepatitis.
First, the company finished dosing the severe alcoholic hepatitis patients receiving 90 milligrams (90 mg) of DUR-928.
Second, the dose escalation committee approved moving into the 150 mg dose part of the study. Enrollment for this final dose level cohort, also patients with severe alcoholic hepatitis, will begin soon.
The committee gave the green light after reviewing safety and pharmacokinetic data from the already completed dose cohorts. "Preliminary data from the completed cohort of severe alcoholic hepatitis patients dosed at 90 mg are consistent with the preliminary data from 30 mg and 90 mg patients we reported last month," President and CEO James E. Brown said in the release.[NLINSERT]
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: DURECT Corp. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.